Vvax 001

Drug Profile

Vvax 001

Alternative Names: rSFVeE6,7; Semliki Forest Virus Based Cancer Vaccine; SFVeE6,7; Vvax-001

Latest Information Update: 18 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ViciniVax
  • Developer University of Groningen
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Human papillomavirus E6 protein inhibitors; Human papillomavirus E7 protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cervical intraepithelial neoplasia

Most Recent Events

  • 28 Nov 2017 ViciniVax completes a phase I trial in Cervical intraepithelial neoplasia in Netherlands (IM) (NCT03141463)
  • 13 Jan 2017 Phase-I clinical trials in Cervical intraepithelial neoplasia in Netherlands (IM) (NCT03141463)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cervical-intraepithelial-neoplasia in Netherlands (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top